The EPS miss combined with withdrawn guidance and canceled earnings call is a major red flag. The May 7 announcement referenced in the filing is likely material and negative, traders should review that 8-K immediately. The stock is likely to sell off sharply on the EPS miss and uncertainty. Monitor for any further disclosures about the May 7 event.
CPRX drugs
CPRX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 12 $31.14entry
- T+1 · 6mo ago 0.00%α −0.54% · $31.14
- T+5 · 6mo ago +0.29%α +0.21% · $31.23
- T+20 · 5mo ago +0.64%α +2.37% · $31.34
- T+60 · due 3mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Catalyst Pharmaceuticals reported Q1 2026 GAAP diluted EPS of $0.50 on total revenue of $149.4M, missing the consensus estimate of $0.64 EPS and $148.2M revenue. The company withdrew forward guidance and canceled its earnings call following a May 7 announcement, creating significant uncertainty despite strong underlying product revenue growth from FIRDAPSE and AGAMREE.
Key Financial Metrics
Key Facts
- GAAP diluted EPS of $0.50 missed consensus estimate of $0.64 by 21.9%
- Total revenue of $149.4M was slightly above consensus of $148.2M (beat by 0.8%)
- Non-GAAP diluted EPS of $0.79 was reported, but Street consensus tracks GAAP EPS for pharma
- FIRDAPSE revenue grew 18.1% YoY to $98.9M; AGAMREE grew 66.6% to $36.7M
- FYCOMPA revenue declined 61.3% YoY to $13.8M following loss of exclusivity
- Company withdrew forward-looking guidance and canceled earnings call citing May 7 announcement
- Cash and equivalents of $755.9M with no funded debt as of March 31, 2026
- GAAP net income grew 12.3% YoY to $63.7M; operating income grew 15.6% to $73.2M
Financial Impact
GAAP diluted EPS of $0.50 vs $0.64 consensus (-21.9% miss); revenue $149.4M vs $148.2M consensus (+0.8% beat)
Risk Factors
- Withdrawn guidance and canceled earnings call signal significant uncertainty
- FYCOMPA revenue decline of 61.3% YoY due to loss of exclusivity may accelerate
- May 7 announcement could involve regulatory, legal, or operational setback
- EPS miss of 21.9% vs consensus undermines credibility of prior guidance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292348 |
Track record
16 reports on CPRX
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +25.72% at T+60 after the Feb 25, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 No price data
- Aug 22, 202612w ago Institutional Cluster Mixed 5/10 No price data
- Jul 24, 202616w ago 15-12G Bearish 9/10 Entry $31.49 No price data
- Jul 17, 202617w ago EFFECT Bearish 5/10 Entry $31.49 No price data
- Jul 15, 202617w ago 25-NSE Bearish 9/10 Entry $31.49 No price data
- Jul 8, 202618w ago 8-K Bullish 6/10 Entry $31.47 No price data
- Jun 30, 202619w ago DEFA14A Neutral 3/10 Entry $31.44 No price data
- Jun 30, 202619w ago 8-K Neutral 4/10 Entry $31.44 No price data
- May 28, 202624w ago PREM14A Bullish 8/10 Entry $31.23 to $31.46 ▲ +0.74% +2.53% vs SPY
- May 12, 202626w ago DEFA14A Neutral 3/10 Entry $31.14 to $31.34 ▲ +0.64% +2.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers